Campbell & CO Investment Adviser LLC
Position in GH — Guardant Health, Inc.
CIK 1353570
BALTIMORE, MD
Position in GH
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,484,286
+$3,181,287 QoQ
Shares Held
48,547
+280.6% QoQ
Ownership
0.037%
of shares outstanding
% of Portfolio
0.26%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GH Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026Campbell & CO Investment Adviser LLC holds $54,655,619 across 18 Diagnostics & Research names. GH ranks #4 (8.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | A |
Agilent Technologies, Inc.
|
89,159 | $10,162,342 | |
| 2 | DHR |
Danaher Corp /De/
|
33,267 | $6,307,423 | |
| 3 | WAT |
Waters Corp /De/
|
16,002 | $4,765,395 | |
| 4 | GH |
Guardant Health, Inc.
This page
|
48,547 | $4,484,286 | |
| 5 | IDXX |
Idexx Laboratories Inc /De
|
7,772 | $4,367,009 | |
| 6 | TMO |
Thermo Fisher Scientific Inc.
|
7,448 | $3,660,915 | |
| 7 | CSTL |
Castle Biosciences Inc
|
148,824 | $3,653,629 | |
| 8 | VCYT |
Veracyte, Inc.
|
106,443 | $3,428,529 |
All Filings in GH
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,484,286 | 48,547 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,302,999 | 12,757 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,188,869 | 19,028 | Shares | Sole | 2025-10-28 | |
| 2024-12-31 | $1,722,683 | 56,389 | Shares | Sole | 2025-02-10 | |
| 2023-09-30 | $960,217 | 32,396 | Shares | Sole | 2023-11-08 | |
| No filing history on record for this holder in this stock. | ||||||